Cancer centers push patients to quit smoking
By Carla K. Johnson article
When cancer patients stop smoking, they heal faster, experience fewer side effects from treatment, and lower their chances of tumors returning. Now, top cancer hospitals are helping patients quit as evidence mounts that it s never too late.
The newest research, reported Monday, shows lung cancer patients who stopped smoking gained nearly two years of life compared to those who continued to smoke. It is a huge effect, said Dr. Mahdi Sheikh, who led the study for the World Health Organization s cancer research agency in Lyon, France. In lung cancer, he said, quitting smoking is as necessary as the treatments.
Arquer Diagnostics ADXBLADDER Becomes First Bladder Cancer Urine Test To Undergo Rigorous Clinical Trials In USA
First patients recruited for bladder cancer recurrence monitoring study
News provided by
Share this article
SUNDERLAND, England, July 27, 2021 /PRNewswire/
ADXBLADDER has become the first new generation urinary biomarker test for bladder cancer to undergo rigorous clinical trials in the USA in decades. The innovative and highly accurate test, developed by UK company Arquer Diagnostics, is already approved for use across Europe.
ADXBLADDER is now being evaluated in a bladder cancer recurrence monitoring study in the US. With results of the study expected by the end of 2021, Arquer Diagnostics hopes to make a 510(k) premarket submission to the US Food and Drug Administration (FDA) to gain clearance from the organisation for
Hits: 207
SAN FRANCISCO, CA, USA and SUZHOU, China I July 25, 2021 I Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the first patient has been dosed in a Phase 1 study of IBI321, an anti-PD-1/TIGIT bispecific antibody.
The objective of this open-label, multi-center Phase 1a dose escalation and expansion study is to evaluate the safety, tolerability, potential optimal dosage and preliminary efficacy of IBI321 in patients with advanced malignant tumors whose cancer progressed on standard-of-care treatment. The trial is being conducted in China.
Our redesigned local news and weather app is live! Download it foriOS or Android and sign up for alerts.
“It’s the biggest reason I’ve ever had in my life to quit,” said Preston Browning, an electrician in Ridgetop, Tennessee, who quit cigarettes last month while recovering from cancer surgery.
Browning, now 20 years old, had smoked a pack a day since he was 14. He credits the stop-smoking drug Chantix and support from tobacco treatment specialists at the Vanderbilt-Ingram Cancer Center. Nurse Lesa Abney listened to Browning’s reasons for smoking he described smoking as “me time” and “a little reward” and suggested strategies he could use: Eat breakfast instead of lighting up each morning. Reach for a toothpick after lunch. Treat yourself with dessert.
| Crain s New York Business | Covering gender-affirming treatments will save health plans money, advocates say crainsnewyork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from crainsnewyork.com Daily Mail and Mail on Sunday newspapers.